BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Nakazuru S, Yoshio T, Suemura S, Itoh M, Araki M, Yoshioka C, Ohta M, Sueyoshi Y, Ohta T, Hasegawa H, Morita K, Toyama T, Kuzushita N, Kodama Y, Mano M, Mita E. Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report. World J Gastroenterol 2010; 16(30): 3853-3856 [PMID: 20698050 DOI: 10.3748/wjg.v16.i30.3853]
URL: https://www.wjgnet.com/1007-9327/full/v16/i30/3853.htm
Number Citing Articles
1
Marie Buchholz, Johanna Strotmann, Britta Majchrzak-Stiller, Stephan Hahn, Ilka Peters, Julian Horn, Thomas Müller, Philipp Höhn, Waldemar Uhl, Chris Braumann. New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In VivoCancers 2022; 14(11): 2685 doi: 10.3390/cancers14112685
2
Megan Finch-Edmondson, Marius Sudol. Framework to function: mechanosensitive regulators of gene transcriptionCellular & Molecular Biology Letters 2016; 21(1) doi: 10.1186/s11658-016-0028-7